Contact Us
Drug Search Results
More Filters [+]

CS-917

Alternative Names: cs-917, cs917, cs 917
Latest Update: 2024-01-09
Latest Update Note: PubMed Publication

Product Description

Antidiabetic (gluconeogenesis inhibitor) (Sourced from: https://www.daiichisankyo.com/files/news/ir/pdf/005171/ser2005_11_07_19_03.pdf)

Mechanisms of Action: PFKFB3 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Daiichi Sankyo
Company Location: TOKYO M0 103-8426
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CS-917

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2004-003195-11

P2

Completed

Type 2 Diabetes

2005-08-09

CS0917-A-U205

P2

Completed

Type 2 Diabetes

None

Recent News Events

Date

Type

Title

01/09/2024

PubMed

 The translational potential of miR-26 in atherosclerosis and development of agents for its target genes ACC1/2, COL1A1, CPT1A, FBP1, DGAT2, and SMAD7.

03/14/2022

PubMed

 Player-aware resource compensation in interrupted cricket matches.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions